View ValuationGenomtec 将来の成長Future 基準チェック /06現在、 Genomtecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.お知らせ • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).お知らせ • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).お知らせ • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).お知らせ • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).お知らせ • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.分析記事 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023お知らせ • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Genomtec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:GMT - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20260-9-9-9N/A12/31/20250-10-11-11N/A9/30/20250-11-8-8N/A6/30/20250-12-13-13N/A3/31/20250-12-13-13N/A12/31/20240-11-7-7N/A9/30/20240-12-10-10N/A6/30/20240-11-6-5N/A3/31/20240-10-6-4N/A12/31/20230-9-11-8N/A9/30/20230-13-11-7N/A6/30/20230-12-10-5N/A3/31/20230-13-9-5N/A12/31/20220-12-8-4N/A9/30/20220-8-7-4N/A6/30/20220-7-7-5N/A3/31/20220-6-5-4N/A12/31/20210-7-6-5N/A9/30/20210-14-4-3N/A6/30/20210-14-4-3N/A3/31/20210-12-4-4N/A12/31/20200-11-3-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GMTの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: GMTの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: GMTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: GMTの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: GMTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GMTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 20:34終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genomtec S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).
Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025
New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).
お知らせ • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.
Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).
お知らせ • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).
お知らせ • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024
New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).
Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).
お知らせ • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.
分析記事 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023
お知らせ • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021